SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as investors aggressively debate whether the asset is finally primed for a breakout following recent price consolidation, with community sentiment deeply polarized between bullish expectations of institutional adoption via regulatory clarity and skeptical claims that the coin remains a manipulated vehicle for Ripple leadership. Discussions are heavily focused on technical patterns, exchange transfer trends to cold wallets, and ongoing comparisons to Bitcoin's price action, reflecting a community eager for a definitive market trend shift.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing increased investor activity and conversation centered on its potential for a short squeeze, driven by significant short interest and speculation regarding future M&A activity. The community is closely monitoring upcoming earnings and pipeline data, specifically around the navenibart program, as a potential catalyst to move the stock out of its long-term trading range.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is trending following a significant surge driven by the release of positive Phase 1 expansion data for its colorectal cancer candidate, Varsetatug Masetecan. The community is actively discussing the stock's massive long-term gains, while debates persist over whether this movement is a sustainable breakout fueled by potential buyout interest or a speculative pump-and-dump scenario.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is capturing significant investor attention as the company approaches critical catalysts, including a pending U.S. patent and a May 31 PDUFA target date for its ADHD treatment, CTx-1301. The community is actively discussing the stock's potential for significant upside due to its low float and the massive total addressable market for ADHD, while recent institutional funding and leadership updates have bolstered confidence in the company's commercial readiness.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is trending as the community debates its pivot to an AI-native mortgage platform and the impact of upcoming institutional partnerships, while traders weigh the volatility caused by high short interest and speculative options activity.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending as retail momentum surges following reports of renewed AI hardware demand and increased options activity surrounding its Gemini-II chip. The community is actively debating the company's long-term competitive viability in edge AI versus GPU incumbents, while traders speculate on potential buyout interest and upcoming technical benchmarks.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is experiencing significant market volatility as investors weigh potential data center growth against frustration over delayed tenant announcements and recent secondary share registrations. While bullish participants highlight the company's Permian Basin infrastructure and long-term potential in the AI-driven energy sector, the community is deeply divided between those accumulating shares on dips and skeptics demanding concrete project updates.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore is trending as traders react to federal intervention, specifically the U.S. government's use of the Defense Production Act to potentially override California environmental regulations and expedite the restart of stalled oil pipeline operations. The community remains heavily divided between bulls anticipating a massive short squeeze driven by the federal backing and bears focused on the company's precarious financial position, pending litigation, and ongoing SEC investigations.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

Mistery ($MERY) is trending as a prominent meme coin on the Cronos blockchain, driven by its strong correlation with $CRO and community enthusiasm regarding its 'rug-proof' security profile. Investors are actively discussing the token's growth potential by comparing it to historical meme coin success stories and monitoring significant accumulation by the crypto.com/us exchange.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is trending as investors react to a massive new long-term infrastructure agreement with Meta, which follows closely behind a multi-billion dollar strategic investment from Nvidia. The community is actively debating the stock's valuation and long-term potential as a primary AI compute provider, while closely monitoring the potential for a short squeeze amidst heavy volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Achieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above 200 Day Moving Average - Time to Sell...

Achieve Life Sciences, Inc. $ACHV Shares Sold by Propel Bio Management LLC

Propel Bio Management LLC lowered its position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) by 38.5% during the third quarter, according to its most recent disclosure with the...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat...

Achieve Life Sciences (ACHV) Expected to Announce Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 10. (View Earnings Report at...

Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200 Day Moving Average - What's Next?

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened...

Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have earned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the company...

Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above 200-Day Moving Average - Here's Why

Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above Two Hundred Day Moving Average - What's Next...

What is HC Wainwright's Forecast for ACHV FY2030 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - HC Wainwright issued their FY2030 EPS estimates for shares of Achieve Life Sciences in a note issued to investors on Monday, January 26th. HC...

Achieve Life Sciences (NASDAQ:ACHV) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened

Achieve Life Sciences (NASDAQ:ACHV) Shares Pass Above Two Hundred Day Moving Average - Time to Sell...

Achieve Life Sciences Promotes Mark Rubinstein As Chief Medical Officer

(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said Monday it has confirmed the promotion of Mark Rubinstein from Interim Chief Medical Officer to...

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.29	--	--	N/A
Q3 '25	-$0.24	-$0.28	-14.75%	MISSED
Q2 '25	-$0.37	-$0.37	-1.09%	MISSED
Q1 '25	-$0.38	-$0.37	3.06%	BEAT
Q4 '24	-$0.34	-$0.36	-5.49%	MISSED

ACHV
Achieve Life Sciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ACHV News

ACHVAchieve Life Sciences Inc.